Page last updated: 2024-08-21

psilocybin and Refractory Depression

psilocybin has been researched along with Refractory Depression in 33 studies

Research

Studies (33)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	12 (36.36)	24.3611
2020's	21 (63.64)	2.80

Authors

Authors	Studies
Castle, D; Ceban, F; Gill, H; Ho, R; Lee, Y; Lin, K; Ling, S; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM	1
Agin-Liebes, G; Davis, AK	1
Brand, M; Gründer, G; Kärtner, L; Mertens, LJ; Scharf, D; Schmitz, C; Spangemacher, M	1
Johannesdottir, A; Sigurdsson, E	1
Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U	1
Aaronson, ST; Alvarez, O; Arden, PC; Baker, A; Bennett, JC; Bird, C; Blom, RE; Brennan, C; Brusch, D; Burke, L; Campbell-Coker, K; Carhart-Harris, R; Cattell, J; Daniel, A; DeBattista, C; Dunlop, BW; Eisen, K; Feifel, D; Forbes, M; Goodwin, GM; Haumann, HM; Hellerstein, DJ; Hoppe, AI; Husain, MI; Jelen, LA; Kamphuis, J; Kawasaki, J; Kelly, JR; Key, RE; Kishon, R; Knatz Peck, S; Knight, G; Koolen, MHB; Lean, M; Licht, RW; Malievskaia, E; Maples-Keller, JL; Mars, J; Marwood, L; McElhiney, MC; Miller, TL; Mirow, A; Mistry, S; Mletzko-Crowe, T; Modlin, LN; Nielsen, RE; Nielson, EM; O'Keane, V; Offerhaus, SR; Páleníček, T; Printz, D; Rademaker, MC; Reinholdt, F; Repantis, D; Rucker, J; Rudow, S; Ruffell, S; Rush, AJ; Schoevers, RA; Seynaeve, M; Shao, S; Soares, JC; Somers, M; Stansfield, SC; Sterling, D; Strockis, A; Tsai, J; van Reemst, A; Visser, L; Wahba, M; Williams, S; Young, AH; Ywema, P; Zisook, S	1
Madras, BK	1
Iacobucci, G	1
Gukasyan, N	1
Hieronymus, F; Østergaard, SD	1
Benyamina, A; Dervaux, A; Roméo, B	1
Courtet, P; Lengvenyte, A; Olié, E	1
Goodwin, GM; Hellerstein, DJ; Young, AH	1
Nichols, CD; Thompson, SM; Wulff, AB	1
Castle, DJ; Meikle, SE; Rossell, SL; Williams, ML	1
Jha, MK; Kamal, S; Radhakrishnan, R	1
Chen, MH; Su, TP; Tu, PC	1
Croal, M; Feifel, D; Goodwin, GM; Kelly, JR; Malievskaia, E; Marwood, L; Mistry, S; O'Keane, V; Peck, SK; Simmons, H; Sisa, C; Stansfield, SC; Tsai, J; Williams, S	1
Aaronson, ST; Alexander, JL; Baron, DA; Garakani, A; Gross, LS; Pine, JH; Raison, CL; Sumner, CR	1
Carhart-Harris, RL; Demetriou, L; Mertens, LJ; Nutt, DJ; Roseman, L; Wall, MB	1
Tullis, P	1
Carhart-Harris, RL; Curran, HV; Freeman, TP; Hindocha, C; Lawn, W; Leech, R; Nutt, DJ; Stroud, JB	1
Bloomfield, M; Bolstridge, M; Carhart-Harris, RL; Curran, HV; Day, CMJ; Erritzoe, DE; Feilding, A; Forbes, B; Giribaldi, B; Kaelen, M; Nutt, DJ; Pilling, S; Rickard, JA; Rucker, J; Taylor, D; Watts, R	1
Carhart-Harris, RL; Demetriou, L; Nutt, DJ; Roseman, L; Wall, MB	1
Carhart-Harris, RL; Lyons, T	1
Carhart-Harris, R; Evans, L; Feilding, A; Giribaldi, B; Kaelen, M; Nutt, D; Raine, J; Rodriguez, N; Roseman, L; Timmerman, C	1
Ashton, P; Carhart-Harris, RL; Carrillo, F; Fernández Slezak, D; Fitzgerald, L; Nutt, DJ; Sigman, M; Stroud, J	1
Carhart-Harris, RL; Erritzoe, D; Kaelen, M; MacLean, K; Nour, MM; Nutt, DJ; Roseman, L	1
Bloomfield, M; Bolstridge, M; Carhart-Harris, RL; Curran, VH; Day, CM; Erritzoe, D; Feilding, A; Forbes, B; Kaelen, M; Nutt, DJ; Pilling, S; Rickard, JA; Rucker, J; Taylor, D	1
Cowen, P	1
Hendrie, C; Pickles, A	1
Flynn, S; Frowde, KD; Jelen, LA; Rucker, JJ; Young, AH	1
Patra, S	1

Reviews

9 review(s) available for psilocybin and Refractory Depression

Article	Year
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS drugs, 2022, Volume: 36, Issue:1 Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Psilocybin	2022
[Are psychedelics fast acting antidepressant agents?] Der Nervenarzt, 2022, Volume: 93, Issue:3 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Psychiatry	2022
[The use of psilocybin for treatment-resistant depression]. Laeknabladid, 2022, Volume: 108, Issue:9 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Randomized Controlled Trials as Topic	2022
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. International journal of molecular sciences, 2022, Sep-28, Volume: 23, Issue:19 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin	2022
Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. Neuropharmacology, 2023, 06-15, Volume: 231 Topics: Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Inflammation; Psilocybin; United States	2023
Role of Psychedelics in Treatment-Resistant Depression. The Psychiatric clinics of North America, 2023, Volume: 46, Issue:2 Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin	2023
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal of psychiatric practice, 2023, 09-01, Volume: 29, Issue:5 Topics: Anxiety; Anxiety Disorders; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psychedelics in the treatment of unipolar mood disorders: a systematic review. Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:12 Topics: Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mood Disorders; Pilot Projects; Psilocybin; Treatment Outcome	2016
Return of the psychedelics: Psilocybin for treatment resistant depression. Asian journal of psychiatry, 2016, Volume: 24 Topics: Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2016

Trials

7 trial(s) available for psilocybin and Refractory Depression

Article	Year
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England journal of medicine, 2022, 11-03, Volume: 387, Issue:18 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Psilocybin; Treatment Outcome	2022
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023, Volume: 48, Issue:10 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Psilocybin; Treatment Outcome	2023
Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. Journal of psychopharmacology (Oxford, England), 2020, Volume: 34, Issue:2 Topics: Adult; Amygdala; Brain Mapping; Depressive Disorder, Treatment-Resistant; Emotions; Facial Expression; Female; Hallucinogens; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Photic Stimulation; Prefrontal Cortex; Psilocybin; Treatment Outcome	2020
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 2018, Volume: 235, Issue:2 Topics: Adult; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Feasibility Studies; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Psilocybin; Psychosocial Support Systems; Time Factors; Treatment Outcome	2018
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology, 2018, Volume: 142 Topics: Adult; Amygdala; Antidepressive Agents; Brain Mapping; Combined Modality Therapy; Depressive Disorder, Treatment-Resistant; Emotions; Facial Recognition; Female; Hallucinogens; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Psilocybin; Psychotherapy	2018
Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. Journal of affective disorders, 2018, 04-01, Volume: 230 Topics: Adult; Algorithms; Antidepressive Agents; Case-Control Studies; Depressive Disorder, Treatment-Resistant; Female; Hallucinogens; Humans; Language; Machine Learning; Male; Memory, Episodic; Middle Aged; Psilocybin; Speech; Speech Production Measurement	2018
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The lancet. Psychiatry, 2016, Volume: 3, Issue:7 Topics: Adult; Depressive Disorder, Treatment-Resistant; Feasibility Studies; Female; Humans; Male; Middle Aged; Psilocybin; Serotonin Receptor Agonists; Social Support; Treatment Outcome	2016

Other Studies

17 other study(ies) available for psilocybin and Refractory Depression

Article	Year
Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences, 2022, Volume: 56 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2022
Psilocybin in Treatment-Resistant Depression. The New England journal of medicine, 2022, 11-03, Volume: 387, Issue:18 Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2022
Psilocybin reduces symptoms in treatment resistant depression, trial results show. BMJ (Clinical research ed.), 2022, 11-02, Volume: 379 Topics: Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2022
On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. Med (New York, N.Y.), 2023, 01-13, Volume: 4, Issue:1 Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Suicide	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. Reply. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Why didn't the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder? The Australian and New Zealand journal of psychiatry, 2023, Volume: 57, Issue:7 Topics: Australia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Psychotherapy	2023
Next generation antidepressants with novel mechanisms for treatment resistant depression. Progress in brain research, 2023, Volume: 278 Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
How ecstasy and psilocybin are shaking up psychiatry. Nature, 2021, Volume: 589, Issue:7843 Topics: Animals; Certification; Clinical Trials as Topic; Depression; Depressive Disorder, Treatment-Resistant; Drug Prescriptions; Efficiency; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; N,N-Dimethyltryptamine; Neuronal Plasticity; Niacin; Psilocybin; Psychiatry; Psychotherapy; Rumination, Cognitive; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress Disorders, Post-Traumatic	2021
Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology, 2018, Volume: 235, Issue:2 Topics: Adult; Depressive Disorder, Treatment-Resistant; Emotions; Facial Expression; Facial Recognition; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Pilot Projects; Psilocybin; Psychosocial Support Systems; Treatment Outcome; Young Adult	2018
Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of psychopharmacology (Oxford, England), 2018, Volume: 32, Issue:7 Topics: Adult; Authoritarianism; Case-Control Studies; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Environment; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Pilot Projects; Politics; Psilocybin; Severity of Illness Index; Surveys and Questionnaires; Time Factors	2018
The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology, 2018, Volume: 235, Issue:2 Topics: Adult; Auditory Perception; Depressive Disorder, Treatment-Resistant; Emotions; Female; Hallucinogens; Humans; Male; Music; Music Therapy; Psilocybin; Psychotherapy	2018
Effects of psilocybin therapy on personality structure. Acta psychiatrica Scandinavica, 2018, Volume: 138, Issue:5 Topics: Adult; Depressive Disorder, Treatment-Resistant; Extraversion, Psychological; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Neuroticism; Personality; Psilocybin	2018
Altered states: psilocybin for treatment-resistant depression. The lancet. Psychiatry, 2016, Volume: 3, Issue:7 Topics: Depression; Depressive Disorder, Treatment-Resistant; Feasibility Studies; Hallucinogens; Humans; Psilocybin	2016
Psilocybin: panacea or placebo? The lancet. Psychiatry, 2016, Volume: 3, Issue:9 Topics: Depression; Depressive Disorder, Treatment-Resistant; Feasibility Studies; Hallucinogens; Humans; Psilocybin	2016